GLOW Extends the Case for Fixed-Duration CLL Therapy

Company Johnson & Johnson / AbbVie Event Type Clinical Data / Final Trial Analysis Modality Fixed-Duration BTK Inhibitor + BCL2 Inhibitor Doublet Asset Ibrutinib + Venetoclax Target BTK / BCL2 Disease Area Chronic Lymphocytic Leukemia (Older/Comorbid, Untreated) Summary The final GLOW analysis reports durable progression-free…